Saturday 17 October 2026
Export CLRB’s income statement to Excel — free account
Cellectar Biosciences, Inc.
CLRB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.2% and free cash flow fell 17.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.14
0.05
−4.20%
Follow CLRB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 3,000.00 | 3,240.00 | 366.00 | 312.00 | 303.00 | 174.00 | 37.50 | 39.00 | 6.60 | 2.45 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 36,900.00 | 9,210.00 | 4,320.00 | 1,125.00 | 999.00 | 894.00 | 237.00 | 94.50 | 133.50 | 20.70 | |||||
| People | |||||||||||||||
| People | Employees | 15 | 15 | 7 | 8 | 11 | 12 | 15 | 20 | 11 | 11 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (6) | (14) | (13) | (14) | (15) | (24) | (32) | (43) | (45) | (22) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (6) | (14) | (13) | (14) | (15) | (24) | (32) | (43) | (45) | (22) | |||||
| Depreciation | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (4,084.08) | (3,213.21) | (1,570.57) | (552.55) | (228.23) | (129.13) | (121.62) | (93.39) | (36.64) | (8.35) | |||||
| Cash flow | (5,521.47) | (2,344.74) | (1,155.77) | (456.79) | (211.10) | (122.06) | (107.33) | (79.55) | (38.98) | (8.86) | |||||
| Capex | (48.20) | (73.77) | (33.33) | (0.96) | (0.95) | (0.76) | (0.96) | (2.12) | (0.09) | 0.00 | |||||
| Free cash flow | (5,569.67) | (2,418.51) | (1,189.10) | (457.74) | (212.05) | (122.82) | (108.29) | (81.67) | (39.07) | (8.87) | |||||
| Book value | 9,026.60 | 2,288.19 | 1,339.49 | 353.88 | 830.22 | 178.72 | 34.69 | (37.25) | 11.71 | 3.27 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (8) | (11) | (11) | (12) | (14) | (23) | (25) | (32) | (48) | (23) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | |||||
| Free cash flow | (8) | (11) | (12) | (12) | (14) | (23) | (25) | (33) | (48) | (23) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 11 | 8 | 12 | 9 | 54 | 33 | 9 | (15) | 15 | 9 | ||||
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 1 | — | — | — | |||||
| Net debt | (11) | (10) | (13) | (11) | (57) | (36) | (20) | (10) | (23) | (13) | |||||
| Shareholders’ equity | 14 | 11 | 13 | 9 | 55 | 33 | 8 | (15) | 14 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (81.67) | (106.48) | (110.87) | (103.23) | (42.57) | (50.33) | (108.15) | (254.09) | (237.45) | (107.74) | ||||
| ROIC | (288.74) | (1,222.58) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (130.69) | (133.83) | (151.08) | (151.16) | (70.75) | (72.63) | (159.70) | 732.16 | 1,470.68 | (200.01) | |||||
Negative figures in brackets.
Fiscal years to Dec 2009 · latest quarter Mar 2010
Charts ten years each
Cellectar Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INAB IN8bio, Inc. | $11.7M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENSC Ensysce Biosciences, Inc. | $11.6M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTN Palatin Technologies, Inc. | $11.6M | — (loss-making) | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| CLRB Cellectar Biosciences, Inc. | $11.2M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | |
| INTS Intensity Therapeutics Inc. | $11.0M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PHIO Phio Pharmaceuticals Corp. | $10.8M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TPST Tempest Therapeutics, Inc. | $10.7M | — (loss-making) | — | −71.57% (below 0%: shrinking) | n/m | +67.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KPRX Kiora Pharmaceuticals, Inc. | $10.7M | — (loss-making) | — (loss-making) | −93.64% (below 0%: shrinking) | n/m | +50.06% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $11.3M | — | — | −15.10% | — | +16.11% | 0.00% | 0.00% |
Cellectar Biosciences, Inc. (CLRB) key facts
- Cellectar Biosciences, Inc. (CLRB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CLRB traded at $1.14, a market capitalization of $11.2 million.
- Return on equity was −200.0% and debt-to-equity 0.00.